The US Department of Transportation (DOT) issued a Final Order granting approval of, and antitrust immunity for, the proposed alliance agreements submitted by Delta Air Lines and Aeromexico. 

Delta and Aeromexico have proposed to use the antitrust immunity to operate a joint venture between the US and Mexico and will coordinate their network planning, pricing, and sales activities, as well as enhance the alignment of their respective frequent flyer program.

The Department determined that the proposed alliance, as conditioned, has the potential to provide substantial benefits for the traveling public, including broader connectivity between the United States and Mexico.

US-based Delta Air Lines is reportedly thinking of bringing back complementary meals to economy class passengers. According to a number of bloggers, the experiment is carried out on long-haul routes connecting New York City and the West Coast. This in-flight amenity has not been provided by US carriers since 2010.

The Department also identified a number of competitive issues that could prevent the public from realizing those benefits, if left unchecked, and developed conditions to ensure that approval of the alliance is pro-consumer. 

Among those conditions, is the requirement that the carriers divest takeoff and landing authorizations (slots) to support 24 new daily trans-border services from Mexico City and four new daily trans-border services from New York JFK to be operated by competing airlines.

Aeromexico, Mexico's Airline, announced the launch of Aerobot, a chatbot (automated system which engages in conversation with a user) for Facebook Messenger which lets customers search for flight and other information.

US DOT found these conditions necessary to prevent harm to consumers that would result from the carriers’ dominant positions at MEX airport and JFK airport and the inability of new entrant carriers to access slots at the airports.  The slot divestitures would occur over the spring and fall of 2017. 

The Department  also finalized other conditions on its approval, including limiting the grant of immunity to five years.